Followers | 228 |
Posts | 14837 |
Boards Moderated | 1 |
Alias Born | 03/29/2014 |
![](https://investorshub.advfn.com/uicon/467032.png?cb=1478627184)
Wednesday, March 27, 2024 8:27:26 PM
We know that even getting rid of egfrviii and egfr wildtype, provides no durability as a monotherapy.
Right, because when egfrv3 was targeted using rindopepimut, the tumor simply returned without that variant present.
I was wondering if you, or anyone else, would be interested in reviewing an analysis I'd put together regarding what appear to be significant errors with the study presented in 2016 by NEJM of the single GBM patient that received CAR T IL13BB? treatment for his tumor.
https://www.nejm.org/doi/full/10.1056/NEJMoa1610497
I do suspect that this P1 trial may have paved the way for the next trial that was recently published in the NEJM.
https://www.nejm.org/doi/full/10.1056/NEJMoa2314390
I ask because because I believe there are two significant things wrong with the study as it was presented.
1. The authors present that a large spinal tumor was "discovered" after a second round of the Car-T therapy was given, but they claim that the spinal column tumor (multifocal leptomeningeal disease) was a result of the previous treatment given in a trial (clinical trial NCT01975701 for BGJ398, an FGFR inhibitor). I give reasons why I think this in my analysis... which I admit... could be wrong.
2. The authors indicate a glowing 7.5 month CR period that I believe to be incorrect, and that perhaps, at most, the response was around 2 months. In my analysis, I state why I think that.
We report that autologous CAR T cells targeting IL13Ra2 mediated a transient complete response in a patient with recurrent multifocal glioblastoma, with dramatic improvements in quality of life, including the discontinuation of systemic glucocorticoids and a return to normal life activities.
It is for these reasons that I wondered if anyone on the board would be interested in and have the time to look at what I'd found to see if they agree, or what I might have missed. I'd written this analysis more like a letter to the NEJM quite some time ago, but decided against sending it to them, or bringing it up here as I did think at the time, that the company might have been pursuing publication of their results in the NEJM for the interim data. And without vetting it, I couldn't know if I was right in what I was seeing. And now, with all the hoopla concerning Car-T and its magnificent results with regards to GBM, I'm curious if others agree with my thinking.
If you, or anyone other critical thinkers are interested in reading through my thinking on the matter, I'll post my reasoning here, and would welcome any response or corrections as to what I may have missed. It's a bit lengthy, which is why I ask. And I'm really looking for constructive critique, as I'd hate to go further with this if I'm incorrect.
Thanks!
:)
Recent NWBO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/13/2024 08:01:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 09:06:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 02:42:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/30/2024 11:49:38 PM
- Biophma Announces Exclusive In License for Dendritic Cell Technology, Sending Shares Higher • AllPennyStocks.com • 06/17/2024 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 09:11:16 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/03/2024 09:22:55 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 05/22/2024 08:13:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 09:04:57 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM